Search
Design Therapeutics Inc
DSGNAdd to Watchlist
13.990USD
+0.220+1.60%
Close 08-07 16:00（ET）Quotes delayed by 15 min
875.50MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-07The current earnings forecast score of Design Therapeutics Inc is 8.86, ranking 47 out of 387 in the Biotechnology & Medical Research industry. The average price target is 12.50, with a high of 15.00 and a low of 7.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
21.000
Target Price
+52.51%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Design Therapeutics Inc
DSGN
7
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Design Therapeutics Inc's price target?
Analysts forecast that Design Therapeutics Inc's price target is USD 12.50, with the highest forecast at USD 15.00 and the lowest forecast at USD 7.00.
How have Design Therapeutics IncDSGN's recent earnings per share performed?
The market expectation was USD -0.32, while Design Therapeutics IncDSGN's earnings per share (EPS) for the previous quarter was USD -0.29. EPS for the next quarter is expected at USD -0.36.
What is the analyst rating for Design Therapeutics Inc?
Based on the ratings of Design Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.